Scinai Immunotherapeutics Ltd. announced its Annual General Meeting of Shareholders on June 16, 2026, to re-elect directors, amend Articles to increase authorized Ordinary Shares, approve executive compensation, and ratify auditors.
Key takeaways
Annual General Meeting scheduled for June 16, 2026 at 4 p.m. Israel time in Tel Aviv.
Re-election proposed for directors Sam Moed, Yael Margolin (3-year terms) and Adi Raviv (2-year term).
Amendment to Articles to increase authorized Ordinary Shares requires 75% approval.
Compensation proposals for CEO Amir Reichman (employment amendment, 2026 RSUs) and Chairman Mark Germain (service extension, RSUs).
Ratification of Ziv Haft (BDO member) as auditors for 2026.
3,959,792 ADSs outstanding as of May 11, 2026, each representing 4,000 Ordinary Shares; record date May 13, 2026.